Browsing Tag
Novo Nordisk
79 posts
Novo Nordisk advances amycretin to phase 3 after early data show weight loss of up to 24% in obesity trials
Novo Nordisk moves amycretin to phase 3 after early trials show up to 24% weight loss. See what makes this dual-receptor drug a next-gen obesity contender.
Novo Nordisk’s high-dose Wegovy delivers 21% weight loss in STEP UP Phase 3 trial results
Novo Nordisk’s high-dose Wegovy led to 21% weight loss in a Phase 3 trial. Learn what the STEP UP data means for obesity care and future regulatory plans.
Deep Apple Therapeutics signs $812m global deal with Novo Nordisk for oral cardiometabolic drugs
Deep Apple inks up to $812M deal with Novo Nordisk to advance oral GPCR drugs for obesity and metabolic diseases. Explore the science behind the strategy.
Why Alzheimer’s partnerships with Roche, BMS, and Novo Nordisk still matter for Prothena
Explore how Prothena’s strategic collaborations with Roche, BMS, and Novo Nordisk could shape the future of Alzheimer’s drug development.
Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints
Prothena ends birtamimab development after failed Phase 3 trial in AL amyloidosis. Find out how this impacts its pipeline, financials, and future direction.
Hims & Hers Health soars over 10% after Wegovy rollout, Q1 strength, and analyst upgrades
Hims & Hers Health stock jumped 10.36% on May 16, 2025, after a Wegovy rollout, strong Q1 earnings, and analyst upgrades boosted investor confidence.
U.S. stock market top losers: Globant, Newegg, Doximity, and Applied Materials among biggest decliners
Explore the full list of U.S. stock market’s biggest losers on May 16, 2025. Find out why Globant, Doximity, and 19 other stocks fell amid rising market uncertainty.
Novo Nordisk and Septerna forge $2.2bn GPCR deal to develop oral therapies for obesity and diabetes
Novo Nordisk partners with Septerna in a $2.2B deal to develop oral GPCR therapies for obesity and diabetes. Explore the full stock sentiment and deal impact.
Eli Lilly’s oral weight-loss pill shakes Novo Nordisk as investors brace for market shift
Novo Nordisk shares drop after Eli Lilly’s oral weight-loss pill shows promise. Analysts see a shifting obesity drug market. What this means for investors.
Novo Nordisk’s Mim8 shows promising efficacy and safety in haemophilia A children, phase 3 interim results reveal
Novo Nordisk A/S has announced encouraging interim results from its phase 3 FRONTIER3 clinical trial, highlighting the potential…